An observational study in Critical Illness, Geriatric Patient and Mortality, sponsored by Ankara Etlik City Hospital. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Ankara Etlik City Hospital · Observational
"This prospective observational study aims to evaluate the prognostic value of dynamic changes in the serum uric acid-to-albumin ratio (UAR) measured on admission (Day 0) and on Day 3, along with mNUTRIC and PNI scores, regarding 28-day mortality in intensive care patients aged 65 and older."
"As the elderly population in intensive care units (ICUs) continues to grow, identifying reliable and accessible prognostic markers for mortality becomes increasingly critical. This study is designed as a single-center, prospective observational cohort study conducted at Ankara Etlik City Hospital. A total of 224 patients aged 65 and older who stay in the ICU for at least 72 hours will be evaluated.
The primary objective is to investigate whether the dynamic changes in the Uric Acid-to-Albumin Ratio (UAR) between admission and the 3rd day of ICU stay-combined with nutritional and clinical risk scores such as mNUTRIC, PNI, APACHE II, and SOFA-can reliably predict 28-day all-cause mortality. Laboratory parameters, routine biochemistry, hemogram, and clinical outcomes including mechanical ventilation duration and total ICU length of stay will be systematically recorded."
1,923 studies on the registry are indexed under Critical Illness; 465 are open to participants now.
This study's planned enrollment of 224 is above the median of 130 across 883 observational studies indexed under Critical Illness.
Browse Critical Illness studies →Ankara Etlik City Hospital is the lead sponsor of 172 studies on the registry; 77 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients aged 65 and older who were admitted to the intensive care units of Ankara Etlik City Hospital and followed for at least 72 hours.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients aged 65 and older who were hospitalized in the intensive care unit for at least 72 hours
Other: Uric Acid to Albumin Ratio (UAR) and Nutritional Risk Scores
Observational evaluation of biomarkers and clinical scores.
28-day Mortality
All-cause mortality evaluated up to 28 days following intensive care unit admission, and its prognostic relationship with the dynamic changes in serum uric acid-to-albumin ratio (UAR) between admission and Day 3, along with baseline mNUTRIC and PNI scores.
Time frame: 28 days
Plan to share: Undecided — Individual participant data will not be shared due to institutional data privacy regulations and ethical restrictions regarding patient confidentiality.
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Jun 2027, 7 months later.
Of 473 non-industry observational studies under Critical Illness, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 43. This study's planned 7 months is below that.
Counting every sponsor, half of 477 studies reached it within 22 months; a quarter within 11 and three quarters within 43.
Critical Illness covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.